|1.||Lai, Ching-Lung: 19 articles (04/2015 - 12/2002)|
|2.||Ahn, Sang Hoon: 17 articles (11/2015 - 01/2009)|
|3.||Han, Kwang-Hyub: 17 articles (11/2015 - 03/2006)|
|4.||Chang, Ting-Tsung: 16 articles (01/2014 - 10/2005)|
|5.||Tang, Hong: 14 articles (06/2015 - 01/2011)|
|6.||Kumada, Hiromitsu: 14 articles (01/2014 - 06/2007)|
|7.||Park, Jun Yong: 12 articles (11/2015 - 01/2009)|
|8.||Hu, Tsung-Hui: 12 articles (11/2015 - 01/2012)|
|9.||Janssen, Harry L A: 12 articles (08/2015 - 01/2008)|
|10.||Yuen, Man-Fung: 12 articles (04/2015 - 01/2006)|
|1.||Chronic Hepatitis B
11/14/2014 - "Several clinical trials have demonstrated the potent antiviral efficacy of entecavir (ETV), and this relatively new nucleoside analogue drug has rapidly become a frequently prescribed therapy for chronic hepatitis B (CHB) worldwide. "
11/01/2013 - "Entecavir (Baraclude®, Bristol-Myers Squibb) is a potent and selective antiviral agent that has demonstrated efficacy in patients with chronic hepatitis B. "
04/01/2010 - "To assess therapeutic efficacy in this clinical setting, we retrospectively examined treatment endpoints among the subset of nucleoside-naïve chronic hepatitis B (CHB) patients treated in phase 3 clinical trials of entecavir who had both screening and baseline serum ALT 1.3 to 2 x ULN. "
05/01/2012 - "Entecavir is an effective treatment for chronic hepatitis B. "
03/01/2011 - "Long-term treatment with entecavir resulted in durable virologic suppression and continued histologic improvement in nucleoside-naive chronic hepatitis B patients. "
03/01/2008 - "Based on the results of this study, entecavir is likely to be cost-effective in treating hepatitis B patients in China based on the World Health Organization's recommended maximum willingness to pay threshold."
01/01/2014 - "Entecavir is considered a first-line therapeutic option for hepatitis B, due to its demonstrated efficacy in rapidly suppressing the viral load. "
05/01/2013 - "Entecavir is one of the therapeutic options currently available for the management of chronic hepatitis B. "
02/01/2009 - "[Case-controlled study of entecavir treatment for chronic severe hepatitis B]."
09/01/2015 - "The blood tests and cross-sectional area (mm(2)) of the psoas major muscle on computed tomography were measured before and after long-term entecavir therapy (median, 39 mo; range, 14-76 mo) in patients with hepatitis B (17 men, 13 women; mean age, 63 ± 13 y). "
01/01/2014 - "The high efficacy of entecavir, associated with its safety profile, its high genetic barrier to resistance and its cost-effectiveness, allowed this molecule to become one of the preferred first-line options of treatment to manage HBV infections. "
02/01/2006 - "Entecavir is a new antiviral agent for the management of chronic HBV infection. "
12/01/2012 - "A nucleoside analogue was added (entecavir) and the patient cleared hepatitis C virus (HCV) infection and seroconverted to anti-HBs. "
04/10/2008 - "Short-term antiviral therapy with the nucleoside analogue entecavir (ETV), given at an early stage of duck hepatitis B virus (DHBV) infection, restricts virus spread and leads to clearance of DHBV-infected hepatocytes in approximately 50% of ETV-treated ducks, whereas widespread and persistent DHBV infection develops in 100% of untreated ducks. "
01/01/2016 - "Entecavir (ETV) has been shown to be safe and efficacious in randomised controlled trials in highly selected patients with hepatitis B virus (HBV) infection. "
08/01/2014 - "Combination therapy of Fufang Biejia Ruangan tablet plus entecavir is effective for treating HBV-related cirrhosis."
01/01/2012 - "Although entecavir has been shown to improve health outcomes in a cost-effective manner in mixed populations of CHB patients, the cost-effectiveness of entecavir has not been evaluated in CHB patients with decompensated cirrhosis. "
07/20/2015 - "In the present study, we aimed to evaluate the efficacy of entecavir therapy by monitoring virological response at the end of the 3 rd month of treatment and try to figure out whether baseline factors could help predict it in a cohort of hepatitis B virus (HBV) compensated cirrhosis patients and to determine the cut-off value of a predicting parameter. "
07/07/2015 - "Long-term antiviral efficacy of entecavir and liver histology improvement in Chinese patients with hepatitis B virus-related cirrhosis."
03/01/2012 - "[Efficacy of entecavir treatment in hepatitis B virus-related decompensated cirrhosis]."
|5.||Liver Diseases (Liver Disease)
05/01/2006 - "The availability of entecavir as a new treatment option is providing clinicians more choice to keep both viral replication and liver disease under control. "
01/01/2014 - "His liver dysfunction improved after administration of entecavir. "
09/01/2013 - "This study investigated the influence of virological response (VR) to entecavir on clinical liver disease progression in nucleos(t)ide analogue (NA)-naive and -experienced patients. "
09/01/2013 - "Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants."
12/24/2011 - "In conclusion, entecavir is a valuable agent for the first-line treatment of chronic hepatitis B in patients with decompensated liver disease."
|3.||Hepatitis B e Antigens
|8.||adefovir dipivoxil (Hepsera)
|9.||DNA (Deoxyribonucleic Acid)
|10.||tenofovir disoproxil (Viread)
|2.||Drug Therapy (Chemotherapy)
|3.||Transplantation (Transplant Recipients)
|5.||Combination Drug Therapy (Combination Chemotherapy)